Following U.S. Stocks were among the “Top Gainers” during Monday’s trade:CorMedix Inc (NYSEMKT:CRMD), TI BioPharma (NASDAQ:CTIC), Accelerate Diagnostics (NASDAQ:AXDX), XOMA (NASDAQ:XOMA)
Their insights are depicted underneath:
CorMedix Inc (NYSEMKT:CRMD)’s shares picked up 6.42%, and closed at $8.78, hitting new 52-week high of $9.34.
Through PRNewswire, CorMedix, Inc. (CRMD), a pharmaceutical corporation focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, declared that the extension to April 30, 2015 of the expiration date applies to all publicly traded warrants.
CorMedix Inc., a development-stage pharmaceutical and medical device corporation, intends to in-license, develop, and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases.
The holders of CorMedix warrants should note that the Corporation issued two tranches of warrants in 2010 with the same CUSIP number (No.21900C118). The first tranche of warrants were purchased for cash in connection with the Corporation’s initial public offering of ordinary stock in 2010, and may be exercised at the specified exercise price in exchange for registered, freely tradable shares of ordinary stock issued following a presently effective registration statement.
The second tranche of warrants was also issued in 2010 to a select group of investors in exchange for debt issued preceding to the Corporation’s initial public offering. The holders of these warrants may exercise and receive in exchange shares of unregistered ordinary stock. The Corporation intends to file a registration statement for the resale of the shares issuable upon exercise of the second tranche of warrants as soon as practicable following the filing later this week of the Corporation’s Annual Report Form 10-K.
CorMedix Inc. is a commercial-stage pharmaceutical corporation that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases.
CTI BioPharma Corp (NASDAQ:CTIC), raised 6.42%, and closed at $2.82.
Through PRNewswire, CTI BioPharma Corp. (CTIC), and Baxter International Inc. (BAX) declared positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis. The PERSIST-1 trial met its primary endpoint in the intent-to-treat population with statistically noteworthy activity observed in patients irrespective of their initial platelet count, counting patients with very low platelet counts at study entry, a condition known as severe or life-threatening thrombocytopenia.
The primary endpoint of the trial was the proportion of patients achieving a 35 percent or greater reduction in spleen volume from baseline to Week 24 as measured by magnetic resonance imaging (MRI) or computerized tomography (CT) when contrast with physician-specified best accessible therapy (BAT), not including treatment with JAK2 inhibitors. The PERSIST-1 trial demonstrated that pacritinib treatment offered a clinically and statistically noteworthy response rate (p = 0.0003) in spleen volume reduction in patients with myelofibrosis when contrast to BAT. Importantly, the trial results also demonstrated a noteworthy difference among patients with platelet counts of less than 100,000 per microliter and less than 50,000 per microliter, both subgroups that were stratified at randomization. The magnitude of treatment effect was consistent with formerly stated Phase 2 results, with the greatest reduction observed among the sickest patients (platelet counts).
The safety profile in the PERSIST-1 trial was consistent with preceding Phase 2 trials. While the most ordinary treatment emergent adverse events were diarrhea, nausea and vomiting, the incidence of grade 3 events was lower than observed in Phase 2 trials. No grade 4 gastrointestinal adverse events were stated. Three patients suspended therapy and nine patients required dose reduction for diarrhea. Preliminary analysis suggests that very few patients suspended treatment while on pacritinib or required a dose reduction due to treatment-related anemia or thrombocytopenia. Additional data from ongoing analyses together with top-line results from PERSIST-1 will be presented for presentation at an forthcoming scientific meeting.
CTI BioPharma Corp. (NASDAQ:CTIC) is a biopharmaceutical corporation focused on the attainment, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
Accelerate Diagnostics Inc (NASDAQ:AXDX), enhanced 5.95%, and closed at $19.23.
Accelerate Diagnostics, Inc. (AXDX), an in vitro diagnostics corporation dedicated to providing solutions for the global challenge of drug resistant organisms and hospital attained infections, declared that Lawrence Mehren, Chief Executive Officer, presented a corporate update at the Cowen and Corporation 35th Annual Health Care Conference in Boston, MA on Wednesday, March 4th at 8:00AM ET.
Accelerate Diagnostics, Inc. focuses on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.
XOMA Corp (NASDAQ:XOMA), rose 5.04%, and closed at $3.75.
Through GLOBE NEWSWIRE, XOMA Corporation (XOMA), a leader in the discovery and development of therapeutic antibodies, declared the presentation of data from XOMA 358, the lead antibody in the Corporation’s XMet D program, at the Endocrine Society’s Annual Meeting — ENDO 2015. Paul Rubin, M.D., Senior Vice President, Research and Development, and Chief Medical Officer at XOMA, presented the Corporation’s data, titled “XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial”.
“The XOMA 358 Phase 1 data is the first to show that a monoclonal antibody can down-regulate the insulin receptor and its downstream signaling. Insulin is the primary hormone in blood glucose regulation, and there are several rare diseases where the body produces inappropriately high levels of insulin, causing dangerously low blood sugars. This condition, which can lead to brain damage or, in rare cases, death, often requires extensive therapy counting continuous ingestion of glucose or even pancreatectomy,” stated Dr. Rubin. “Our results suggest XOMA 358 is a first-in-class molecule active against the insulin receptor and shows potential for treatment of patients who experience this endogenous over-production of insulin.”
XOMA’s innovative product candidates are the result of the Corporation’s expertise in developing ground-breaking monoclonal antibodies, counting allosteric modulating antibodies, which have created new opportunities to potentially treat a wide range of human diseases.
